Martin David Harp

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

The meeting kicks off with symposia and an opening keynote speech from Ed Yong

Josefina Botta, MD, MSc, discusses her real-world experiences with the RayOne EMV toric lens

The technology, which creates a 360-degree, instantaneous capsulotomy, appeared at the Eyecelerator event

At ASCRS, Dr Rom Kandavel discusses iStent outcomes for patients who have undergone laser peripheral iridotomy, trabeculectomy and SLT

At this year's ASCRS meeting, J. Morgan Micheletti, MD, talks about his research and the Young Eye Surgeons (YES) programme

Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis

A reduction in clinical exposure has harmed student confidence, according to a questionnaire administered in the United Kingdom

A look back at some of the biggest stories in 2023, from our US partners at Ophthalmology Times

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Analysis of data from the European Union and the United States showed low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI

Academy’s program will take place in San Francisco, California, 3-6 November 2023, before returning to Chicago, Illinois in 2024

Every October, World Sight Day brings awareness to the global challenges of blindness and vision impairment

ARCATUS, also known as XIPERE®, utilises a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Nicholas Volpe, MD shares insights from his talk titled "Optic Neuropathy Versus Maculopathy" at the European Society of Ophthalmology Congress being held in Prague.